Modality
Bispecific Ab
MOA
TROP-2 ADC
Target
PLK4
Pathway
Angiogenesis
PVSchizophreniaPNH
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
~Aug 2021
→ ~Nov 2022
Phase 3
Feb 2023
→ May 2030
Phase 3Current
NCT07468238
2,911 pts·PV
2023-02→2027-03·Completed
NCT04506417
1,940 pts·PNH
2025-08→TBD·Recruiting
NCT05075765
2,691 pts·Schizophrenia
2025-12→2027-10·Active
+1 more trial
10,365 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-03-2512mo awayPh3 Readout· PV
2027-10-211.6y awayPh3 Readout· Schizophrenia
2030-05-094.1y awayPh3 Readout· Schizophrenia
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Recruit…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2027-03-25 · 12mo away
PV
Ph3 Readout
2027-10-21 · 1.6y away
Schizophrenia
Ph3 Readout
2030-05-09 · 4.1y away
Schizophrenia
RecruitingActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07468238 | Phase 3 | PV | Completed | 2911 | UPCR |
| NCT04506417 | Phase 3 | PNH | Recruiting | 1940 | EDSS |
| NCT05075765 | Phase 3 | Schizophrenia | Active | 2691 | LiverFat |
| NCT07881382 | Phase 3 | Schizophrenia | Recruiting | 2823 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |